Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.

Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same period in 2010.  Increased operating expenses for the fourth quarter of 2011 and for the full calendar year compared to the same periods in 2010 are primarily due to increased research and development expenses associated with our Phase 2b PEARL-SC clinical study in patients with Systemic Lupus Erythematosus, or lupus, and our VISTA-16 clinical study in patients with Acute Coronary Syndrome, or ACS.

Anthera ended the fourth quarter of 2011 with approximately $67.4 million in cash and cash equivalents and short-term investments.  This is compared to $93.3 million in cash and cash equivalents and short-term investments for the third quarter ended September 30, 2011.

In conjunction with the release of the fourth quarter 2011 financial report, Anthera will host a conference call at 1 p.m. Eastern Time today, February 21, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 47038854. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854.  The audio replay will be available until February 28, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • In December 2011, the VISTA-16 Data Safety Monitoring Board (
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
    (Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
    (Date:9/18/2014)... , Sept. 18, 2014  A $3 million grant ... the University of Michigan to establish a national center ... Glenn Center for Aging Research at U-M will focus ... can slow the effects of aging and postpone diseases ... aging that can help develop medications that may help ...
    Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
    (Date:9/18/2014)... temperatures in the Atlantic Ocean may be allowing certain ... becoming warmer, an expansion that could pose a significant ... of 40 species along the reefs off the North ... poisonous lionfish, according to researchers from the National Oceanic ... Carolina-Wilmington, who published their findings in the September issue ...
    (Date:9/18/2014)... PITTSBURGH, PA (PRWEB) September 18, 2014 ... efficient patient care while also maintaining the patient's privacy," ... came up with this idea in order to supply ... jobs well." , They created a prototype for The ... The device enables staff to turn patient onto his ...
    (Date:9/18/2014)... Texas (PRWEB) September 18, 2014 One ... the air medical transport industry, ShandsCair Flight Program’s ... Airbus Helicopters Inc . (AHI) at the Air Medical ... The recently delivered and placed into service ShandsCair EC155 ... that will be displayed at AMTC highlight Airbus Helicopters ...
    (Date:9/18/2014)... Alan Mozes HealthDay ... When it comes to emergency room waiting times, patients seeking ... time staring down the clock than those seen at smaller ... of crowding and our ability to provide timely emergency care ... of the authors of the new research, Dr. Renee Hsia, ...
    (Date:9/18/2014)... proven it true: exercise is good for you. But ... exercise may have an added benefit for cancer patients ... model of melanoma, found that combining exercise with chemotherapy ... Libonati, an associate professor in the School of Nursing ... Nursing Research, was the senior author on the study, ...
    Breaking Medicine News(10 mins):Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2
    ... A new cafe called the Dana Cafe Light Lounge has ... overcoming the winter blues//. A dose of light is given ... produced by the dark winter days in the country. The ... in the country, which can result in depression. Most ...
    ... have to wait long before they were given treatment, which ... workers are seriously agitating against this issue and want doctors ... ,Though the trust feel that the actions of ... number of patients attending the hospitals during winter has been ...
    ... Norwich Union Healthcare reveals that the number of people claiming to ... magazines. The results were based on a survey of 250 general ... 250 GP’s; almost 167 of them said that they had seen ... 187 said that it was psychological. ,What they ...
    ... Health Minister Xavier Bertrand as said that the French government ... from a pandemic bird flu infection, the ministry has presented ... has a population of 62 million and the minister said ... and has ordered more than 40 million flu vaccines. The ...
    ... disgraced scientist from South Korea has formally apologized for ... your forgiveness," he said// in a televised press conference ... feel so miserable that it's difficult even to say ... University panel investigating Hwang concluded he had never cloned ...
    ... the prude university say that the long winter might make ... will keep away their winter blues//. ,Jane Kinyon, ... it is very common to suffer from mild irritation and ... sunlight and freezing temperatures. But this should not dampen one’s ...
    Cached Medicine News:
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: